MERAI

Full name

MERAI – MeVis and Radboudumc AI Lab

Research Lines

  • Accuracy
  • Resilience

Sustainable Development Goals

The research of the MERAI Lab is about developing AI-supported software solutions for healthcare to improve the accuracy of imaging interpretation in the lung oncology field, reduce the time needed to report scans, and improve the cost-effectiveness of the healthcare system. MERAI Lab is a collaboration between Radboud UMC and MeVis Medical Solutions.

We expect recruitment for this lab to open in early 2023. Please check back frequently for updated information about how to apply, and to register for an online information session in February. If you’d like to join our mailing list, please fill out the form, and we will be happy to keep you informed of all the latest developments.

Healthcare costs are globally rising. The workload of radiology departments has substantially increased and is still increasing, and, as a result, radiologists are under large pressure and risk of burn-out. The imminent implementation of lung cancer screening and the rapid increase in the availability of novel cancer treatments such as immunotherapy will result in a large increase in imaging. One key technology which has the potential to reduce the workload of radiologists is artificial intelligence. Simple, repetitive tasks can be taken over by AI algorithms, leaving more difficult and context-dependent differential diagnosis questions to radiologists and putting more focus on reporting to patients (human-centric care). In addition, we foresee a demand and chance for trained human readers, not necessarily medical specialists, aided by AI to prescreen images before being sent to radiologists. Ultimately, autonomous AI will be able to triage screening scans such that only abnormal studies and a subset of studies about which AI is uncertain need to be interpreted by human experts.

The MERAI Lab is focused on creating world-leading AI-supported software solutions for healthcare. Our mission is to develop AI algorithms that can improve the accuracy of imaging interpretation in the lung oncology field, reduce the time needed to report scans, and improve the cost-effectiveness of the healthcare system. To ensure the responsible use of these algorithms, the MERAI Lab aims to create robust and trustworthy AI solutions that perform at a level close to human experts. The lab will also evaluate and validate the AI technology it develops, using a global network of hospitals to assess its impact on healthcare.

To improve the accuracy of AI and facilitate its adoption in society, the MERAI Lab will employ a number of strategies. These include using human-in-the-loop annotation strategies to build large, well-curated databases for training, working with clinical stakeholders to optimize the use case of each developed algorithm, and considering ethical, legal, and societal factors to stimulate successful adoption. The lab will also focus on resilience, specifically through the development of efficient out-of-distribution detection methods to cope with distributional shifts. By implementing these strategies, the MERAI Lab hopes to create AI solutions that are reliable and effective in improving healthcare outcomes.

Sustainable Development Goals

MERAI Lab is part of the ROBUST program on Trustworthy AI-based Systems for Sustainable Growth which is financed under the NWO LTP funding scheme. The MERAI Lab is focused on using artificial intelligence (AI) to improve healthcare outcomes and reduce the number of deaths caused by hazardous chemicals, air, water, and soil pollution, which aligns with Sustainable Development Goal 3. We aim to develop AI solutions for the early detection of diseases, such as lung cancer, which can be caused by risk factors such as tobacco and air pollution. This early detection can lead to better outcomes for patients and reduce the number of deaths from lung cancer. In addition, MERAI Lab’s projects aim to strengthen the capacity for early warning and management of diseases with high mortality and morbidity rates worldwide, which aligns with Sustainable Development Goal 9.

SDG 3: Ensure healthy lives and promote well-being for all at all ages

Target 3.9: By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contamination;
Target 3.d: Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks

SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization, and foster innovation

Target 9.5: Enhance scientific research, and upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending.

Staff

Colin Jacobs

Scientific Director

Assistant Professor, Principal Investigator AI for CT Lung Screening, Department of Medical Imaging, RadboudUMC (Technical Lead)

Mathias Prokop

Scientific Director

Head of Department of Medical imaging, RadboudUMC (Clinical Lead)

Partners

Both Radboudumc and MeVis Medical Solutions are responsible for the collection of data that can be used for the development and validation of developed AI algorithms. MeVis Medical Solutions will have an active role in the implementation of the developed AI algorithms into clinical products.